Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Trained on Recursion’s BioHive-2 and accelerated by NVIDIA, the model achieves near-FEP accuracy at speeds up to 1,000× faster, marking one of the most significant advances yet in AI-enabled drug ...

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

SALT LAKE CITY, Nov. 20, 2024-- The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.